CAPRICOR THERAPEUTICS INC

CAPR stock represents shares of Capricor Therapeutics, Inc., a biotechnology company listed on the Nasdaq Capital Market under the ticker CAPR. The company focuses on developing cell and exosome-based therapies for treating diseases with unmet medical needs. As a clinical-stage biotech, its equity value often reflects pipeline prospects rather than current commercial revenue. Investors typically track CAPR for its scientific milestones, regulatory updates, and cash position rather than traditional earnings metrics.

Recent performance for CAPR depends on clinical trial news, financing activities, and broader biotech sentiment, which can cause sharp moves. Because the stock is sensitive to company-specific catalysts, its price and trading volume may change quickly. For the latest price, percentage change, and recent trading range, please refer to the current CAPR quote and performance data displayed on this page, as those figures update continuously during market hours and after hours.

Evaluating CAPR's valuation is unconventional because the company may have little or no product revenue, so price-to-earnings and similar multiples are often not meaningful. Instead, investors look at cash runway, enterprise value relative to pipeline assets, and comparable clinical-stage biotech transactions. Analysts may use risk-adjusted net present value models. For current valuation metrics such as market capitalization or enterprise value, check the latest CAPR statistics on this page.

CAPR may be eligible for pre-market and after-hours trading sessions through certain brokers, though liquidity is typically lower and spreads wider than during regular Nasdaq hours. Extended-hours trading can be influenced by overnight news, clinical trial announcements, or regulatory filings. Not all brokers support it, and orders may not execute if there is insufficient volume. Check with your brokerage for specific extended-hours availability and rules for CAPR.

Analyzing CAPR's financial performance involves reviewing quarterly and annual filings for cash and cash equivalents, operating expenses, research and development spending, and net loss. Because Capricor is likely pre-revenue or has limited revenue, cash burn rate and runway are critical. Investors also monitor general and administrative costs and any partnership or grant revenue. These figures are available in SEC filings and the financial statements section of this page.

Key risks for CAPR include clinical trial failures, regulatory delays or rejections, reliance on a small pipeline, and the need for additional capital, which can dilute existing shareholders. As a small-cap biotech, its stock may be volatile and thinly traded at times. Competition, manufacturing challenges, and changes in healthcare policy could also affect results. These factors can materially impact the company's prospects and share price, so they should be weighed carefully.